2 V a c cines 36 6 3 0 7 4 36 P edi a tric TB RampD I n v e s tments b y R esea r ch Category 2 0 12 T otal 1 0 2 7 8 8 7 5 Basic Scien c e ID: 931979
Download Presentation The PPT/PDF document "With support from the TB Alliance" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
With support from the TB Alliance
Slide22
V
a
c
cines
$3,663,074 (36%)
Pediatric TB R&D Investments by Research Category 2012 Total: $10,278,875
Basic Science$814,356 (8%)
Drugs$3,819,102 (37%)
Diagnostics$1,017,160 (10%)
Ope
r
a
tional
R
esea
r
ch
$965
,
185 (9%)
Slide3P= public-sec
t
or R&D agen
c
y; C=
Corporation/privat
e sector; M= Multilateral; F=Foundation/philanthropy; P-D= Public-sector development agency*TAG r
eports National Institutes of Health inv
estments in three categories: 1) National Institu
te of Allergy and Infectious Diseases—the largest inve
s
t
or in TB R&D overall; 2) the National Health, Lung and Blood Institute—which did not document investments in pediatric TB R&D; and 3) other NIH institutes and centers.Note: This table records contributions made only by funders investing in pediatric TB R&D in 2012.
2012 Pediatric TB R&D Funders by Rank and Compared with Prior Years
1 U.K. Medical Research Council P $2,644,610 $3,111,533 $408,718 $14,790,087 17.9
Other National Institutes of Health
P $2,624,745 $1,917,849 $1,772,537 $36,646,883 7.2 Institutes and Centers* 3 Company X C $1,718,595 N/A N/A $22,844,099 7.5 4 U.S. National Institute of Allergy and Infectious Diseases* P $954,061 $532,394 $554,003 $169,092,971 0.6 5 Wellcome Trust F $551,017 $2,606,924 $322,682 $13,418,817 4.1 6 Company V C $481,080 N/A N/A $4,297,934 11.2 U.S. President’s Emergency P $450,000 $0 $0 $6,606,609 6.8 Plan for AIDS Relief
2012Rank
Funding Organization
Funder Type
2012Pediatric TB R&DFunding
2011 Pediatric TB R&DFunding
2010Pediatric TB R&DFunding
2012Total TB R&DFunding
P
e
rc
entage
of 2
0
12
T
otal R&D Funding Alloc
a
t
ed
t
o
P
edi
a
trics
Slide48 Canadian Institutes P
$326,268 $661,616 N/A $6,017,561 5.4
of Health Research
9 Australian National Health P
$166,738 $295,363 $153,590 $4,060,791
4.1
and Medical Research Council 10 Danish International P-D $154,993 N/A N/A $323,250 47.9 Development Agency 11 World Health Organization M $85,260 $0 $0 $1,707,923 5.0 12 U.S. Agency for P-D $50,000 N/A N/A $12,174,064 0.4 International Development 13 Norwegian Knowledge Centre P $48,460 N/A N/A $48,460 100.0for the Health Services 14 Indian Council of Medical Research P $23,047 N/A N/A $7,131,390 0.3
Grand Total $10,278,875 2012
Pediatric TB R&D Funders by Rank and Compared with Prior Years (continued)
P= public-sector R&D agency; C= Corporation/
pri
v
ate sector; M= Multilateral; F=Foundation/philanthropy; P-D= Public-sector development agency*TAG reports National Institutes of Health investments in three categories: 1) National Ins
titute of Allergy and Infectious Diseases—the largest investor in TB R&D
overall; 2) the N
ational Health, Lung and Blood Institu
te—which did not document i
nvestments in pediatric TB R&D; and 3) other NIH institutes and centers.Note: This table records contributions made only by funders inve
sting in pediatric TB R&D in 2012.
2012Rank
Funding Organiza
tionFunder Type2012
Pediatric TB R&DFunding2011 Pedia
tric TB R&DFunding2010Pedia
tric TB R&DFunding2012T
otal
TB
R&D
Funding
P
e
rc
entage
of 2
0
12
T
otal R&D Funding Alloc
a
t
ed
t
o
P
edi
a
trics